Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has moved Project PHOENIX into a nationwide virtual data-collection phase, opening enrollment for a regulatory-approved registry that the company designed to support U.S. veterans exposed to burn pits and other toxic environmental hazards.
Project PHOENIX sits within the company's broader CELZ-Biodefense Regenerative BioDefense Initiative, which aims to better understand the health impact of toxic exposures and support future therapeutic development for affected veterans.
The company said the program has now moved from formation into nationwide virtual participant onboarding, longitudinal data collection, and AI-enabled interpretation, following earlier regulatory clearance for its BioDefense Veterans Initiative and Burn Pit Initiative.
According to Creative Medical, the platform is designed to support at least 1,000 veterans across the US, with the ability to scale to additional military and civilian populations in the future.
Many veterans were exposed to burn pits and other environmental hazards during military service, exposures that can lead to long-term respiratory, immune, and systemic health issues. The company said Project PHOENIX was created to build a structured, AI-enabled registry capable of collecting and analyzing large-scale data from this population.
The program also incorporates the company's Toxic Exposure Atlas, a proprietary data engine that the company said is intended to support AI-driven discovery of drugs, biologics, biotherapeutics, and regenerative therapies targeting toxic-exposure-related conditions.
Creative Medical Technology Holdings is a commercial-stage biotechnology company focused on regenerative and immunotherapy-based treatments, with programs spanning immunotherapy, endocrinology, urology, neurology, and orthopedics.